Pilot Study of Duloxetine in Psychological Resilience
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00331799|
Recruitment Status : Completed
First Posted : May 31, 2006
Results First Posted : August 2, 2013
Last Update Posted : August 2, 2013
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder||Drug: Duloxetine||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study of Duloxetine in Psychological Resilience and Its Correlation With Blockade of Serotonin and Norepinephrine Transporter|
|Study Start Date :||April 2007|
|Actual Primary Completion Date :||May 2008|
|Actual Study Completion Date :||July 2008|
Active Comparator: 1
Open label treatment with Duloxetine for 8 weeks with dosing from 30-60 mg.
Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
Other Name: Cymbalta
- Change in Connor Davidson Resilience Scale (CD-RISC) From Baseline to 8 Weeks [ Time Frame: baseline and 8 weeks ]CD-RISC has been psychometrically validated, studied in the general population, as well as in clinical samples. Changes in CD-RISC score have been found to be sensitive to the effect of treatment, and impaired resilience has been demonstrated in subjects with depression relative to normal controls using this scale (Connor and Davidson, 2003). The total score ranges from 0-100, with higher scores indicating greater resilience.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00331799
|United States, North Carolina|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27710|
|Principal Investigator:||Wei Zhang, MD, PhD||Duke University|